Cereno Scientific presents the agenda for the upcoming Capital Markets Day to be held October 17th, 2024

Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascular disease, today announced the agenda for the Capital Markets Day that will be held on Thursday October 17, 2024.

The Capital Markets Day will provide an opportunity for investors, analysts, and media to get insights into Cereno’s clinical and preclinical development portfolio and operations as well as its future growth strategy. The program includes presentations by the Cereno Executive Management Team as well as external speakers

The interest for the Capital Markets Day has been high and the event at Posthuset in Stockholm is fully booked. For those not attending on site, there is an opportunity to participate virtually.

Date: October 17
Time: 13:30–16:30 CET
Venue: Online
Register here: https://lnkd.in/djQdTmsY

Aside from the live streaming, a video of the Capital Markets Day presentations will be shared subsequently on Cereno’s website, Youtube and LinkedIn.

 

AGENDA – Cereno Scientific’s Capital Markets Day, Thursday Oct 17th 13:30 -16:30, 2024
Topic	Speaker
Introduction to Cereno Scientific and current strategic priorities	Sten R. Sörensen CEO, Cereno Scientific
Understanding PAH, a debilitating rare disease	Dr. Raymond Benza Network Director of Pulmonary Hypertension at Mount Sinai Icahn School of Medicine, New York City.
Cereno Scientific’s CS1 in PAH	Dr. Rahul Agrawal, CMO and Head of R&D, Cereno
Cereno Scientific’s CS1 - Phase IIa trial results	Dr. Rahul Agrawal, CMO and Head of R&D, Cereno Nicholas Oakes, Head of Preclinical Development, Cereno Scientific
Investigator and patient perspective of CS1-003 trial	Dr. Jason Guichard, Cardiologist at Prisma Health-Upstate, Assistant Professor of Medicine, University of South Carolina School of Medicine Greenville and investigator in the Phase IIa trial of CS1 in PAH
Next steps for CS1	Dr. Rahul Agrawal, CMO and Head of R&D, Cereno Scientific
Introduction to Fluidda and the innovative Functional Respiratory Imaging technology	Jan De Backer, CEO, Fluidda
Short break
CS014 - current status and future perspectives	Dr. Björn Dahlöf, CSO, Cereno Scientific
CS585 - current status and future perspectives	Dr. Michael Holinstat Prof. at University of Michigan Medical School; and Director Translation Research, Cereno Scientific
Cereno Scientific - future outlook	Sten R. Sörensen CEO, Cereno Scientific
Questions from Audience on site and online	Moderated by Dr. Rahul Agrawal, CMO
Concluding remarks	Sten R. Sörensen CEO, Cereno Scientific

 

 

For further information, please contact:

Henrik Westdahl, Director IR & Communications

Email: [email protected]

Phone: +46 70-817 59 96

 

Sten R. Sörensen, CEO

Email: [email protected]

Phone: +46 73-374 03 74

 

About Cereno Scientific AB

Cereno Scientific develops innovative treatments for rare and common cardiovascular diseases. The lead drug candidate, CS1, is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties. A Phase IIa trial evaluating CS1’s safety, tolerability, and exploratory efficacy in patients with the rare disease pulmonary arterial hypertension (PAH) demonstrated that CS1 was safe, well-tolerated and showed a positive impact on exploratory clinical efficacy parameters. CS1 study data, together with preclinical information, is consistent with reversing pathological remodeling. A collaboration agreement with global healthcare company Abbott allowed Cereno to use their cutting-edge technology CardioMEMS HF System in the trial. Since January 2024, we are delighted that the FDA´s Expanded Access Program will enable patients with PAH, a serious life-threatening disease condition, to gain access to CS1 where no comparable alternative therapy options are available. Cereno’s pipeline comprises two additional programs in development through research collaborations with the University of Michigan. CS014 is a new chemical entity with a multi-fold mechanism of action as an epigenetic modulator – regulating platelet activity, fibrinolysis, and clot stability for the prevention of thrombosis without an increased risk of bleeding as documented in preclinical trials. The drug candidate has also demonstrated a favorable profile in preclinical models of other cardiovascular diseases, such as PAH, with reverse remodeling of pulmonary arterial vessels and effects on vascular fibrosis. On 28th of June, 2024, Cereno initiated a first-in-human Phase I trial of CS014. Preclinical candidate CS585 is an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular disease. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Pulmonary Hypertension and thrombosis prevention without increased risk of bleeding. CS585 was in-licensed from the University of Michigan in 2023. The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. Based in Kendall Square, Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). The Certified Adviser is Carnegie Investment Bank AB, [email protected]. More information is on www.cerenoscientific.com.